Navigation Links
Combo therapies tested to overcome drug resistance in melanoma patients
Date:8/2/2011

the same gene. However, Lo determined that was not the case, an important finding because it means that second-generation drugs targeting BRAF would not work and therefore should not be developed, saving precious time and money.

Lo and his team spent two years studying tissue taken from patients who become resistant to try to determine the mechanisms that helped the cancer evade the inhibitors. In the lab, they also developed drug resistant cell lines, in collaboration with another UCLA lab headed by Dr. Antoni Ribas, also a Jonsson Cancer Center researcher. There are still other mechanisms of resistance in melanoma patients with mutated BRAF who are treated with BRAF inhibitors, which UCLA researchers are seeking to uncover and that may provide even more targets for drug therapy. Cancer operates similarly to a criminal seeking to evade his captors, and the small molecule inhibitors are like the police barricades that seek to block escape. When one of the cell signaling pathways driving resistance is blocked, the cancer finds a way to activate another pathway that will drive its growth. If that pathway is blocked, yet another pathway may be activated. The goal is to find a way to block all the pathways helping the cancer evade therapy at once so the cancer cells die before finding a way around the drugs.

In the lab, Lo and his team would apply one drug at a time to the resistant cancer cells and see what route or pathway the cancer used to escape. They then determined what pathway was being used to evade therapy and found an inhibitor for that. In the end, the researchers identified the most optimal combination of molecules to block the pathways PI3K, mTORC and MEK.

"Normal cells have physiologic safety mechanisms to avert death and this is taken to a higher level by the cancer cell to serve its growth agenda, making single agent targeted therapy insufficient," Lo said. "We have to block several roads, which is what is behind our appro
'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles Health Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Adjuvant combo shows potential for universal influenza vaccine
2. Graphene and spintronics combo looks promising
3. UT Southwestern researchers use drug-radiation combo to eradicate lung cancer
4. Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says
5. New discovery brings customized tuberculosis therapies based on genotype closer to reality
6. Therapies to improve biochemical functions hold promise as treatments for autism
7. Can we get there from here? Translating stem cell research into therapies
8. New mouse model may lead to new therapies for degenerative diseases
9. Study finds therapies using induced pluripotent stem cells could encounter immune rejection problems
10. NIH researchers create comprehensive collection of approved drugs to identify new therapies
11. Go figure: Math model may help researchers with stem cell, cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel experience and ... Over the past decade, ePassports, biometric readers, and secure ... through border control via eGates and Automated Passport Control ... and land borders across the globe. ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... systems. Multimodal biometric systems utilize more than one characteristic ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... against HIV increases the risk of developing clinical West Nile ... January 9th in The Journal of Experimental Medicine. , The ... that encodes a protein called CCR5, which was identified in ... Individuals with two copies of this mutation (CCR5delta32) are ...
... Gene variants determine which humans and which chimpanzees can ... influence nutritional choices and ultimately their health, as well ... a way to live safely in their environments by ... conducted more 65 years ago by a team of ...
... and Michael Emerman and colleagues at the Fred Hutchinson Cancer ... humans may be impaired in the function of a recently ... as HIV. , One of the key components of ... gene was discovered because the version of TRIM5 possessed by ...
Cached Biology News:Genetic mutation linked to West Nile virus infection 2Research updates 65-year-old genetic discovery 2Research updates 65-year-old genetic discovery 3
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... May 13 -, EMERYVILLE, Calif., May 12 Neurobiological,Technologies, ... its fiscal third quarter and the nine months ended March ... 2008 were $3.7 million,compared to $4.9 million for the same ... $5.9 million for the third,quarter of 2008 compared to $7.7 ...
... WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a ... and stem cell research systems,today announced that Mr. ... a corporate presentation at the Rodman & Renshaw,Fifth ... held May,19-20, 2008, at the Le Meridien Beach ...
... Host Investor Conference Call on Monday, May 12, 2008 at 8:30am ... ... May 9 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company ... the treatment of life-threatening,diseases, including renal disease and cancer, today announced its ...
Cached Biology Technology:Neurobiological Technologies Reports Third Quarter Financial Results 2Neurobiological Technologies Reports Third Quarter Financial Results 3Neurobiological Technologies Reports Third Quarter Financial Results 4Neurobiological Technologies Reports Third Quarter Financial Results 5WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... microcapillary flow cytometry accessible to anyone in ... appreciate the latest addition to Guavas on-demand ... surprising affordable, and very compact for higher ... features as absolute cell counts, 6 parameters ...
Biology Products: